BIOXYTRAN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1309 USD | -10.36% |
|
+6.42% | -12.73% |
| Apr. 19 | Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 22 | Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 21.85M |
|---|---|---|---|---|---|
| Net income 2022 | -2M | Net income 2023 | -4M | EV / Sales 2022 | - |
| Net Debt 2022 | 1.87M | Net Debt 2023 | 1.9M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-22.4
x | P/E ratio 2023 |
-4.7
x | Employees | 3 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 43.12% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -10.36% | ||
| 1 week | +6.42% | ||
| Current month | +23.72% | ||
| 1 month | +13.83% | ||
| 3 months | -3.04% | ||
| 6 months | -23.00% | ||
| Current year | -12.73% |
1 week
0.11
0.15
1 month
0.100.15
Current year
0.100.16
1 year
0.070.54
3 years
0.001.25
5 years
0.001.95
10 years
0.001.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Platt
CEO | Chief Executive Officer | 71 | 18-02-28 |
Ola Soderquist
DFI | Director of Finance/CFO | 63 | - |
Leslie Ajayi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Platt
CEO | Chief Executive Officer | 71 | 18-02-28 |
Dale Conaway
BRD | Director/Board Member | 69 | 18-11-01 |
Anders Utter
BRD | Director/Board Member | 57 | 18-11-01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.1309 | -10.36% | 239,093 |
| 24-04-23 | 0.146 | +3.55% | 121,400 |
| 24-04-22 | 0.141 | +6.42% | 55,445 |
| 24-04-19 | 0.1325 | +3.11% | 288,748 |
| 24-04-18 | 0.1285 | +4.47% | 31,600 |
Delayed Quote OTC Markets, April 24, 2024 at 03:59 pm EDT
More quotes
Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.
| 1st Jan change | Capi. | |
|---|---|---|
| -12.73% | 22.9M | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.69% | 22.2B | |
| -16.53% | 21.23B | |
| -9.12% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- BIXT Stock
